InspireMD (NSPR) Q4 2025 Earnings Transcript
InspireMD reported a 62% increase in total revenue to $3.1 million, driven by the U.S. launch of CGuard Prime and international expansion. The company expects 2026 revenue to be between $13 million and $15 million, projecting 45%-65% annual growth.
InspireMD reported significant revenue growth in Q4 2025, with total revenue reaching $3.1 million, a 62% increase. U.S. revenue was $866,000, representing 74% sequential quarter-over-quarter growth, attributed entirely to the launch of CGuard Prime. The company's gross profit was $1.2 million, with a 37.5% margin. InspireMD's U.S. commercial team surpassed 30 members, with most in field roles. The company has completed enrollment for the C-GUARDIANS II clinical trial and targets FDA approval for the TCAR indication in the third quarter. InspireMD expects 2026 revenue to be between $13 million and $15 million, projecting 45%-65% annual growth.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.